Table 2.
Demographic data of patients with MCD according to age of onset.
| N | ≤ 19 y/o | 20–39 y/o | 40–64 y/o | 65–74 y/o | ≥ 75 y/o | P-value |
|---|---|---|---|---|---|---|
| 1038 | 1042 | 895 | 212 | 118 | ||
| Age of onset (yrs) | 11 (5, 16) | 29 (24, 34) | 50 (44, 57) | 68 (67, 71) | 79 (76, 82) | < 0.001a,b,c,d,e,f,g,h,i |
| Age at renal biopsy (yrs)* | 17 (14, 19) | 31 (25, 36) | 51 (45, 58) | 69 (67, 72) | 79 (77, 83) | < 0.001a,b,c,d,e,f,g,h,i |
| Age of enrollment (yrs) | 24 (20, 32) | 38 (32, 44) | 56 (49, 63) | 71 (68, 74) | 81 (78, 84) | < 0.001a,b,c,d,e,f,g,h,i |
| Male, n (%) | 703 (67.7%) | 551 (52.9%) | 447 (49.9%) | 131 (61.8%) | 67 (56.8%) | < 0.001a,b,h |
| Present treatment | ||||||
| Oral PSL | 862 (83.0%) | 927 (89.0%) | 796 (88.9%) | 187 (88.2%) | 109 (92.4%) | < 0.001a,b,d |
| IV mPSL | 57 (5.5%) | 81 (7.8%) | 79 (8.8%) | 26 (12.3%) | 13 (11.0%) | 0.002c |
| Cyclosporine | 539 (51.9%) | 527 (50.6%) | 376 (42.0%) | 76 (35.8%) | 41 (34.7%) | < 0.001b,c,d,e,f,g |
| Mizoribine | 178 (17.1%) | 106 (10.2%) | 98 (10.9%) | 15 (7.1%) | 6 (5.1%) | < 0.001a,b,c,d |
| MMF | 79 (7.6%) | 7 (0.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | < 0.001a,b,c,d |
| Rituximab | 120 (11.6%) | 48 (4.6%) | 29 (3.2%) | 2 (0.9%) | 0 (0.0%) | < 0.001a,b,c,d |
| PSL + cyclosporine | 471 (45.4%) | 477 (45.8%) | 338 (37.8%) | 69 (32.5%) | 40 (33.9%) | < 0.001e,f |
| Dosage of treatment | ||||||
| Oral PSL (mg/day) | 21.5 ± 19.1 | 19.2 ± 16.1 | 22.2 ± 17.9 | 24.0 ± 18.2 | 24.7 ± 17.4 | 0.002e,f,g |
| IV mPSL (mg/day) | 545.5 ± 429.4 | 603.3 ± 294.1 | 564.4 ± 266.3 | 526.7 ± 302.1 | 552.1 ± 222.7 | 0.282 |
| Cyclosporine (mg/day) | 106.3 ± 45.0 | 95.4 ± 39.9 | 89.8 ± 34.9 | 84.4 ± 34.2 | 85.9 ± 30.5 | < 0.001a,b,c |
| Mizoribine (mg/day) | 164.3 ± 84.9 | 145.3 ± 50.9 | 135.7 ± 35.1 | 143.3 ± 17.6 | 108.3 ± 37.6 | 0.031 |
| MMF (mg/day) | 1516.0 ± 472.2 | 906.3 ± 680.6 | – | – | – | 0.014 |
| Rituximab (mg/month) | 585.4 ± 363.6 | 606.7 ± 456.6 | 630.1 ± 495.3 | 300.0 ± 282.8 | – | 0.374 |
| Steroid‑resistant NS | 25 (2.4%) | 40 (3.8%) | 82 (9.2%) | 39 (18.4%) | 27 (22.9%) | < 0.001b,c,d,e,f,g,h |
| SDNS or FRNS | 915 (88.2%) | 803 (77.2%) | 500 (55.9%) | 69 (32.5%) | 33 (28.0%) | < 0.001a,b,c,d,e,f,g,h |
| Persistent UP ≥ 0.5 g/gCr | 83 (8.0%) | 154 (14.8%) | 240 (26.8%) | 67 (31.6%) | 39 (33.1%) | < 0.001a,b,c,e,f,g |
Data are expressed as median (interquartile range), mean ± SD or number (percentage).
MCD minimal change disease, PSL prednisolone, mPSL methylprednisolone, MMF Mycophenolate mofetil, NS nephrotic syndrome, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome.
aP < 0.05, ≤ 19 y/o vs. 20–39 y/o, bP < 0.05, ≤ 19 y/o vs. 40–64 y/o, cP < 0.05, ≤ 19 y/o vs. 65–74 y/o, dP < 0.05, ≤ 19 y/o vs. ≥ 75 y/o, eP < 0.05, 20–39 y/o vs. 40–64 y/o, fP < 0.05, 20–39 y/o vs. 65–74 y/o, gP < 0.05, 20–39 y/o vs. ≥ 75 y/o, hP < 0.05, 40–64 y/o vs. 65–74 y/o, iP < 0.05, 40–64 y/o vs. ≥ 75 y/o. Kruskal–Wallis tests with Bonferroni-corrected P-values.
*Number of missing values, n = 155 (14.9%) in ≤ 19 y/o; n = 98 (9.4%) in 20–39 y/o; n = 60 (6.7%) in 40–64 y/o; n = 29 (13.7%) in 65–74 y/o; n = 11 (9.3%) in ≥ 75 y/o.